During 2018 Q3 the big money sentiment decreased to 1.02. That’s change of 1.46, from 2018Q2’s 2.48. 7 investors sold all, 34 reduced holdings as Karyopharm Therapeutics Inc. ratio dropped. 24 grew stakes while 18 funds took stakes. Funds hold 40.88 million shares thus 2.58% less from 2018Q2’s 41.97 million shares.

Tiaa Cref Llc owns 521,058 shs. 800 were reported by Mark Sheptoff Fincl Planning Ltd Liability. Franklin Resource has invested 0.02% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). United Svcs Automobile Association has invested 0% of its capital in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Hbk Invs Limited Partnership owns 0.01% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 39,900 shs. Los Angeles Cap Mgmt & Equity Rech reported 40,090 shs or 0% of all its holdings. American Intl Gru Inc has invested 0% of its capital in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Tower Limited Liability Co (Trc) owns 392 shs. State Common Retirement Fund reported 53,900 shs. Art Advsrs Limited Liability Co stated it has 0.03% of its capital in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Blackrock reported 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Aqr Capital Ltd reported 19,153 shs stake. Thompson Davis & Comm stated it has 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Dimensional Fund L P owns 260,365 shs. National Bank & Trust Of America De has invested 0% of its capital in Karyopharm Therapeutics Inc. (NASDAQ:KPTI).

Karyopharm Therapeutics Inc. had 20 insider sales and 0 insider buys since August 29, 2018. This’s net activity of $6.17 million. On Monday, November 26 Shacham Sharon sold $105,600 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) or 9,600 shs. Primiano Christopher Brett sold 10,000 shs worth $189,046. Chione Ltd also sold $5.27 million worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shs. $52,500 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was sold by Mirza Mansoor Raza.

Reiterated Karyopharm Therapeutics (NASDAQ:KPTI) Rating.

On Wednesday, 27 February analysts report was issued to investors and clients on Karyopharm Therapeutics (NASDAQ:KPTI) of its “Outperform” Rating restate by research professionals at Wedbush. The market cap company was given $6 target price that would indicate 36.36 % upside potential from the last stock close price.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Ratings Coverage

In total 4 analysts cover Karyopharm Therapeutics (NASDAQ:KPTI). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. (NASDAQ:KPTI) has 100% bullish analysts. With $30 highest and $6 lowest target price, Karyopharm Therapeutics has $17 average target price or 286.36% above the current ($4.4) price. 8 are the (NASDAQ:KPTI)’s ratings reports on Feb 28, 2019 according to StockzIntelligence Inc. On Wednesday, February 27 Wedbush maintained Karyopharm Therapeutics Inc. (NASDAQ:KPTI) rating. Wedbush has “Buy” rating and $6 target. On Friday, November 9 the firm earned “Outperform” rating by Wedbush. On Friday, February 22 the stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Buy” rating given by H.C. Wainwright. On Wednesday, February 27 the firm has “Buy” rating given by RBC Capital Markets. On Wednesday, February 27 the rating was maintained by Robert W. Baird with “Buy”. On Thursday, January 3 Bank of America upgraded the shares of KPTI in report to “Neutral” rating.

KPTI hit $4.4 during the last trading session after $0.48 change.Currently Karyopharm Therapeutics Inc. is downtrending after 4.99% change in last February 28, 2018. KPTI has also 6,033 shares volume. KPTI underperformed by 4.99% the S&P 500.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s earnings release is awaited by WallStreet on March, 21, RTT reports. Analysts expect change of 2.50 % or $0.02 from previous year’s $-0.8 earnings per share compared to current’s $-0.82 earnings per share. Wall Street predicts 3.80 % negative EPS growth as of March, 21.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases.The company has $267.12 million market cap. The Company’s lead drug candidate is Selinexor, which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.Currently it has negative earnings. The firm is also developing KPT-8602 that is in Phase 1/2 study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

For more Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news posted recently go to: Seekingalpha.com, Benzinga.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “FDA accepts Karyopharm’s NDA for selinexor for treatment-resistant multiple myeloma, action date April 6, 2019 – Seeking Alpha” posted on October 07, 2018, “Analysts Slash KaryoPharm (NASDAQ:KPTI) Price Targets By Over 50% After Adcom Setback – Benzinga” on February 27, 2019, “The Biotech Bumps – Seeking Alpha” with a publish date: November 01, 2018, “Karyopharm Therapeutics Inc. (KPTI) CEO Michael Kauffman on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” and the last “Karyopharm: Selective Inhibiting Nuclear Export For Stellar Cancer Treatment – Seeking Alpha” with publication date: January 24, 2019.